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Objectives: PVI is the preferred initial revasculariza-
tion strategy at many centers in patients with critical limb
ischemia (CLI). Using a multicenter, regional database we
sought to determine if previous failed ipsilateral, infraingui-
nal PVI (iiPVI) portends worsened outcomes after subse-
quent lower extremity bypass (LEB) in patients with CLI.
Methods: This is a retrospective cohort analysis of the
Vascular Study Group of New England (VS GNE) database of
infrainguinal lower extremity bypass for CLI (2003-2008).
Study endpoints were major amputation, graft occlusion and
mortality rates at one year, and in-hospital major adverse events
(MAE). Outcomes were determined using Kaplan-Meier analy-
sis and Cox Proportional-Hazard multivariate regression.
Results: Of 1, 153 patients who underwent LEB for
CLI, 71 (6.2%) had a prior failed iiPVI. One year mortality
and in-hospital MAE did not differ between the groups.
Patients undergoing prior iiPVI had significantly higher
rates of graft occlusion and amputation at one year (Table).
Multivariate predictors of 1-yr LEB occlusion were prior
iiPVI (HR 1.8; CI 1.1-2.9), arm vein conduit (HR 1.8; CI
1.1-2.6), and tibial outflow (HR 2.0; CI 1.4-2.9). Multi-
variate predictors of 1-yr major amputation were iiPVI (HR
2.0; CI 1.0-3.7), dialysis (HR 4.2; 2.6-6.6), prior ipsilateral
bypass (HR 1.7; CI 1.1-2.8), tibial outflow (HR 1.9; CI
1.3-2.9), and tissue loss (HR 1.7; CI 1.1-2.7).
Conclusions: Failed iiPVI is an important predictor of

















Occlusion (1-yr) 16% 31% 0.01 16% 24% 0.08
Amputation (1-yr) 14% 23% 0.08 14% 21% 0.03
Death (1-yr) 10% 13% 0.97 10% 10% 0.95
MAE (in-hospital) 29% 32% 0.5 29% 29% 0.91
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SS15.
Sustained 5 Years Performance Analysis of Sequential Com-
pression Biomechanical Device (SCBD) in Critical Limb
Ischaemia (CLI) Patients with Un-reconstructable Periph-
eral Vascular Disease (PVD) vs Primary Amputation in a
Tertiary Referral Vascular Centre With Quality of Time
Without the Symptoms or Toxicity of the Disease
(QTWiST)
Sherif Sultan, Nader Hamada, Wael Tawfick, Anne Fahy,
Niamh Hynes. Vascular & Endovascular Surgery, Western
Vascular Institute, Galway, IrelandObjectives: Our aim was assess the clinical efficacy and
economic viability of a SCBD programme for CLI. Primary
endpoints were sustained clinical improvement and ampu-
tation free survival. Secondary endpoints were Q-TWiST
and cost per QALY.
Methods: From 2004 to 2009, we assessed 4538 pa-
tients with PVD. Of which 707 had CLI and 518 had
intervention, while 189 were not candidates for any inter-
vention. Only 170 patients had joined the SCBD pro-
gramme for three months at three hours bi-daily. We
matched controlled 75 primary amputations. All patients
were Rutherford category 4 or more. The median fol-
low-up was 13 months with average of 18.3 months.
Results: Sustained clinical improvement was reported in
68% of patients. Sustained hemodynamic improvement were
notedwith;Mean toe pressure increased from39.9mmHg to
55.42mmHgwith mean difference in Toe Pressure of 15.49
mmHg p 0.0001; andMean Popliteal flow increased from
35.44cm/sec to 55.91cm/sec with Mean Difference in Pop-
liteal Flow of 20.47cm/sec p 0.0001. Thirty-day mortality
was 0.6%.Mean Amputation-free survival rate was 18months
with limb salvage rate at 5years of 94%. Freedom fromMACE
at 5 Years was 62.5%. All cause survival was 68.4%% at 5 years.
Estimatedmedian Inpatient/Total cost of managing a prima-
ry-amputation patient is €29, 815 compared to €3985 for
SCBD.We treated170patientswith artassist at a cost of €681,
965. However, primary amputation for 75 patients had cost
€2, 236, 125 with poor QALY/QTWiST.
Conclusions: SCBD Improves Quality of Life at a
Community Level. This study provides larger scale evi-
dence that SCBD therapy is a cost-effective and clinically
efficacious solution as it has Superior Limb Salvage, Ame-
liorated Amputation Free Survival, Reduced Length of
Hospital Stay and Provided Rapid Relief of Rest Pain
without any Intervention in Patients with Limited Life
Expectancy.
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A Comparison of Endovascular Revascularization and
Bypass in Regards to Healing Rates of Ischemic
Wounds
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Objectives: Compare wound healing after endovascu-
lar therapy (EV) or lower extremity bypass (LEB) to inves-
tigate equivalence based on tissue results and wound char-
acteristics.
Methods: A retrospective review analyzed 290 patients
undergoing revascularization for an ischemic wound from
January 2004 to December 2008. Inclusion required com-
